Every year at Haymarket Media, we bring in a cohort of about 30 interns for eight weeks over the summer to learn the ropes across our business media, medical communications and internal operations units.
For us here at MM+M, our intern exit interview gets recorded and sent out into the world.
Over the past few weeks on the podcast, you’ve heard from our summer intern, Lola Offenback.
In addition to contributing to our discussions of the top news stories in the Trends segment, she has led insightful conversations with the team at Breakthrough T1D as well as Derrick Gastineau from Currax Pharmaceuticals.
You’ve also seen her reporting appear on our website where she has penned articles about Eli Lilly’s latest Zepbound campaign, Supreme Group’s acquisition of rare disease agency Pivot Design and how Opella shined at Cannes this year.
Though Lola’s time with us comes to an end this Friday, she’s our feature interview for today’s episode – sharing her experiences at MM+M, what she’s learned over the last few weeks as well as how she’ll carry those lessons forward as she heads back to class and then into her post-college career.
For our Trends segment, we’re talking about the good, the bad and the ugly of pharma’s Q2 earnings season.
Music: “Deep Reflection” by DP and Triple Scoop Music.
Check us out at: mmm-online.com
Follow us:
YouTube: @MMM-online
TikTok: @MMMnews
Instagram: @MMMnewsonline
Twitter/X: @MMMnews
LinkedIn: MM+M
To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.
Music: “Deep Reflection” by DP and Triple Scoop Music.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
